Highest-materiality recent filing
Nika Pharmaceuticals dismisses accountant OLAYINKA OYEBOLA & CO, appoints Boladale Lawal & Co
Terminated OLAYINKA OYEBOLA & CO on Oct 2, 2024 after a discovery prompting reconsideration.
Nika Pharmaceuticals hires OLAYINKA OYEBOLA & CO as new auditor
Engaged OLAYINKA OYEBOLA & CO (Chartered Accountants) as independent auditor on September 23, 2024.
Nika cancels May 2024 acquisition of Nika Pharmaceuticals Ltd; auditor resigns
On Aug 18, 2024, board cancelled the acquisition of Nika Pharmaceuticals, Ltd. effective May 9, 2024; subsidiary returned to Savov on Aug 23.
Acquired 100% of Nika Pharmaceuticals, Ltd. from CEO Dimitar Savov for nominal 5,000 BGN (~$2,800).
Nika Pharma acquires 40% of Nika Europe, now owns 80%; buys 4 technologies for $24,683
Merger with Nika BioTechnology gave Nika Pharma an additional 40% stake in Nika Europe Ltd, bringing total to 80%.
Nika Pharmaceuticals completes merger with Nika BioTechnology; increases preferred authorized shares
Merger effective March 1, 2024; Nika BioTech shareholders receive 1 NKPH share per NIKA share.
Nika Pharmaceuticals dismisses auditor BF Borgers, appoints Fruci & Associates
Dismissed independent accountant B F Borgers CPA PC effective February 14, 2024.
Nika Pharmaceuticals provides Form 10 info, discloses ownership and auditor change as former shell
Change of control completed Apr 1, 2022: Dimitar Savov acquired 87% of common stock for $140,000.
Appoints Dr. Darena Stoykova Zlateva as Chief Scientific Officer effective Nov 12, 2022
Dr. Zlateva appointed CSO of Nika Pharmaceuticals effective Nov 12, 2022.
Nika Pharmaceuticals dismisses Pinnacle Accountancy Group, engages BF Borgers CPA as new auditor
Dismissed Pinnacle Accountancy Group of Utah effective August 18, 2022.
Centennial Growth Equities changes name to Nika Pharmaceuticals, authorizes 2.7B shares
Shareholders approved name change from Centennial Growth Equities to Nika Pharmaceuticals.
Centennial Growth Equities acquires exclusive rights to TNG and supplements, exits shell status
Acquired 15-year exclusive rights to manufacture and distribute Thymus Nuclear Glycoprotein (TNG) from VITAL FE.
Centennial Growth Equities changes control; Savov buys 87% stake, becomes CEO
Dimitar Slavchev Savov purchased 11,489,000 shares (87%) from Phil E. Ray and other shareholders, triggering change of control on April 1, 2022.
On November 12, 2022, Nika Pharmaceuticals, Inc. (the “company”) appointed Dr. Darena Stoykova Zlateva as the company’s Chief Scientific Officer (“CSO”).
On April 1, 2022, the board of directors accepted the resignations of Mr. Phil E. Ray and Mrs. A. Terry Ray and appointed Dimitar Slavchev Savov to serve as President, CEO, CFO and Clifford Redekop to serve as Secretary of the Corporation.
Effective as of March 31, 2022, the board of directors appointed Dimitar Slavchev Savov, and Clifford Redekop to serve as the Registrant’s Directors.
Effective as of March 31, 2022, the board of directors appointed Dimitar Slavchev Savov, and Clifford Redekop to serve as the Registrant’s Directors.
On April 1, 2022, the board of directors accepted the resignations of Mr. Phil E. Ray and Mrs. A. Terry Ray and appointed Dimitar Slavchev Savov to serve as President, CEO, CFO and Clifford Redekop to serve as Secretary of the Corporation.
On March 31, 2022, Mr. Phil E. Ray resigned his position as a Director, President and Chief Executive Officer of Centennial Growth Equities, Inc. (the “Registrant ”).
On March 31, 2022, Mrs. A. Terry. Ray resigned his position as a Director and Secretary of Centennial Growth Equities, Inc. (the “Registrant”).
Max materiality 0.85 · Median 0.60 · Most common event other_material